Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6415461 | 0.92 | ACE2 (0.67) | LTA4HACE2MAPTKMT2AFFAR4 | |
| SCHEMBL7072060 | 0.92 | ACE2 (0.67) | LTA4HACE2MAPTKMT2AFFAR4 | |
| SCHEMBL8583479 | 0.92 | ACE2 (0.67) | LTA4HACE2MAPTKMT2AFFAR4 | |
| SCHEMBL22839180 | 0.90 | CYP1A2 (0.59) | LTA4HCYP1A2BLMMAPTKMT2A | |
| SCHEMBL9001608 | 0.88 | ACE2 (0.64) | LTA4HCYP1A2ACE2BLMGABRR1 | |
| SCHEMBL5977939 | 0.88 | ACE2 (0.64) | LTA4HCYP1A2ACE2BLMGABRR1 | |
| SCHEMBL20612872 | 0.88 | ACE2 (0.64) | LTA4HCYP1A2ACE2BLMGABRR1 | |
| SCHEMBL31073666 | 0.88 | ACE2 (0.64) | LTA4HCYP1A2ACE2BLMGABRR1 | |
| SCHEMBL27726701 | 0.87 | LTA4H (0.58) | LTA4HCYP1A2ACE2BLMGABRR1 | |
| SCHEMBL2835395 | 0.86 | CYP1A2 (0.67) | LTA4HCYP1A2ACE2BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081385-A1 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | LUPIN LIMITED (IN) | 2022-03-17 | — | — | US | claimed |
| EP-3906231-A2 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | Lupin Limited (IN) | 2021-11-10 | — | — | EP | claimed |
| CN-113227061-A | Novel salts and polymorphs of bipedac acid | 印度鲁宾有限公司 | 2021-08-06 | — | — | CN | claimed |
| WO-2020141419-A2 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | LUPIN LIMITED (IN) | 2020-07-09 | — | — | WO | claimed |
| US-20220081385-A1 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | LUPIN LIMITED (IN) | 2022-03-17 | — | — | US | disclosed |
| EP-3906231-A2 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | Lupin Limited (IN) | 2021-11-10 | — | — | EP | disclosed |
| CN-113227061-A | Novel salts and polymorphs of bipedac acid | 印度鲁宾有限公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2020141419-A2 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | LUPIN LIMITED (IN) | 2020-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081385-A1 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | HADH, ALDH5A1, ACAD9 | LTA4H 507/4885CYP1A2 168/4885ACE2 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.